Clinical Trial

A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

Study acronym: ATTAIN-1
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study will investigate the efficacy and safety of once daily oral orforglipron in adult participants with obesity or overweight with weight-related comorbidities. The study has two phases: a main phase and an extension phase. The main phase of the study lasted 72 weeks. Participants with prediabetes will continue in the extension for another 2 years.
Protocol Amendment History 1 change
critical Primary endpoint(s) modified 2026-08-15
Trial Details
NCT Number NCT05869903
Lead Sponsor Eli Lilly and Company
Conditions Obesity, Overweight, Overweight or Obesity
Enrollment 3,127 participants
Start Date 2023-06-05
Primary Completion 2025-07-25 (estimated)
Study Completion 2027-10 (estimated)
Updated on ClinicalTrials.gov 2026-08-14